<DOC>
	<DOCNO>NCT02656173</DOCNO>
	<brief_summary>The primary objective study investigate efficacy mirabegron versus placebo male patient OAB symptom take alpha blocker , tamsulosin , BPH .</brief_summary>
	<brief_title>A Phase 4 Study Evaluate Efficacy , Safety , Tolerability Mirabegron Male Subjects With Overactive Bladder ( OAB ) Symptoms , While Taking Alpha Blocker Benign Prostatic Hypertrophy ( BPH )</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<mesh_term>Adrenergic alpha-Antagonists</mesh_term>
	<criteria>Visit 1 ( Screening ) : Patient treatment tamsulosin 0.2mg least 4 week start Screening period Patient history average least 2 episode urgency per 24 hour average 8 micturition per 24 hour last 3 day start Screening period ( verified interview ) . Patient wish child future ( Unique Japan ) . Male subject female spouses/partners childbearing potential must use highly effective contraception consist two form birth control ( least one must barrier method ) , start Screening , continue throughout study period , 28 day final study drug administration . Subject must donate sperm , start Screening , continue throughout study period , 28 day final study drug administration . Patient willing able complete micturition diary questionnaire correctly . Subject agree participate another interventional study receive treatment study . Visit 2 ( Baseline ) : Subject average least 2 episode urgency per 24 hour average 8 micturition per 24 hour base 3day micturition diary Screening period . Visit 1 ( Screening ) : Patient suspect symptom OAB , onset transient ( e.g. , druginduced , psychogenic ) . Patient PVR urine volume &gt; 100 mL Q max &lt; 5 mL/sec . Patient prostatespecific antigen ( PSA ) ≥4 ng/mL . Patient neurogenic bladder ( e.g. , spinalcord lesion damage clearly affect urination ; multiple sclerosis ; Parkinson 's disease ) history surgery cause damage pelvic plexus . Patient urethral stricture bladderneck stenosis . Patient diabetic neuropathy complication . Patient undergone surgical procedure , previous pelvic radiation therapy , hyperthermia therapy may affect urinary tract function . Patient significant stress incontinence postsurgical prostate incontinence , determine Investigator . Patient indwell catheter practice intermittent selfcatheterization . Patient 3 episode recurrent urinary tract infection ( UTI ) within last 6 month . Patient UTI ; prostatitis ; chronic inflammation , interstitial cystitis ; urinary calculus ; previous current malignant disease pelvic organ . Patient concurrent malignancy history malignancy ( within past 5 year ) , except nonmetastatic basalcell squamouscell carcinoma skin treat successfully . Patient serious heart disease , liver disease , kidney disease , immunological disease , lung disease . Patient receive intravesical injection within last 12 month botulinum toxin , resiniferatoxin , capsaicin . Patient receive electrostimulation therapy OAB . Patient receive bladder train program pelvic floor exercise &lt; 28 day prior start Screening period . Patient postural hypotension syncope , hypokalemia , closedangle glaucoma . Patient evidence QT prolongation electrocardiogram ( ECG ) , define QTcF &gt; 450 msec . Patient severe uncontrolled hypertension , define sit systolic blood pressure ( SBP ) &gt; 180 mmHg and/or diastolic blood pressure ( DBP ) &gt; 110 mmHg . Patient clinically significant ECG abnormality , determine Investigator . Patient severe renal impairment , define estimate glomerular filtration rate &lt; 29 mL/min/1.73m2 ; endstage renal disease ; undergoing dialysis . Patient aspartate transaminase ( AST ) alanine transaminase ( ALT ) &gt; 2 time upper limit normal ( ULN ) , gammaglutamyl transferase ( γGT ) &gt; 3 time ULN consider clinically significant Investigator . Patient moderate severe hepatic impairment , define ChildPugh Class B C. Patient hypersensitivity component mirabegron , betaadrenergic receptor ( βAR ) agonists , inactive ingredient . Patient ongoing alcohol and/or drug abuse . Patient history mood disorder , neurotic disorder , schizophrenia . Patient dementia , cognitive dysfunction , clinically significant cerebrovascular disorder . Patient treat experimental device &lt; 84 day receive investigational agent &lt; 84 day prior start Screening period . Patient use prohibit concomitant medication &lt; 28 day ( , &lt; 1 year 5αreductase inhibitor ) start Screening period . Patient clinically significant condition , opinion Investigator , make subject unsuitable study participation . Patient involve conduct study employee Astellas group , third party associate study , study site team . Visit 2 ( Baseline ) : Subject fulfills exclusion criterion Visit 1 Visit 2 . Subject noncompliant 4 week tamsulosin Screening period , define take less 80 % great 120 % prescribe dose study medication . Subject average total daily urine volume &gt; 3000 mL , record 3day micturition diary .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Tamsulosin</keyword>
	<keyword>Overactive bladder</keyword>
	<keyword>Benign prostatic hypertrophy</keyword>
	<keyword>Mirabegron</keyword>
</DOC>